| 臺大學術典藏 |
2021-09-04T06:11:19Z |
New perspectives of biomarkers for the management of chronic hepatitis B
|
Lin C.-L.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:19Z |
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
|
Sarin S.K.; Kumar M.; Lau G.K.; Abbas Z.; Chan H.L.Y.; Chen C.J.; Chen D.S.; Chen H.L.; Chen P.J.; Chien R.N.; Dokmeci A.K.; Gane E.; Hou J.L.; Jafri W.; Jia J.; Kim J.H.; Lai C.L.; Lee H.C.; Lim S.G.; Liu C.J.; Locarnini S.; Al Mahtab M.; Mohamed R.; Omata M.; Park J.; Piratvisuth T.; Sharma B.C.; Sollano J.; Wang F.S.; Wei L.; Yuen M.F.; Zheng S.S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:18Z |
Efficacy and resistance to telbivudine treatment in chronic hepatitis B patients with favorable predictors: a multicenter study in Taiwan
|
Wang C.-C.; Lin C.-L.; Hsieh T.-Y.; Tseng K.-C.; Peng C.-Y.; Su T.-H.; Yang S.-S.; Hsu Y.-C.; Chen T.-M.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:18Z |
Hepatitis C viral infection increases the risk of lymphoid-neoplasms: A population-based cohort study
|
Su T.-H.; Liu C.-J.; Tseng T.-C.; Chou S.-W.; Liu C.-H.; Yang H.-C.; Wu S.-J.; Chen P.-J.; Chen D.-S.; Chen C.-L.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:18Z |
Hepatitis C virus infection in Taiwan: Past, present, and future
|
JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:17Z |
Faldaprevir, pegylated interferon, and ribavirin for treatment-na?ve HCV genotype-1: Pooled analysis of two phase 3 trials
|
Jensen D.M.; Asselah T.; Dieterich D.; Foster G.R.; Sulkowski M.S.; Zeuzem S.; Mantry P.; Yoshida E.M.; Moreno C.; Ouzan D.; Wright M.; Morano L.E.; Buynak R.; Bourli?re M.; Hassanein T.; Nishiguchi S.; JIA-HORNG KAO; Omata M.; Paik S.W.; Wong D.K.; Tam E.; Kaita K.; Victor Feinman S.; Stern J.O.; Scherer J.; Quinson A.-M.; Voss F.; Gallivan J.-P.; B?cher W.O.; Ferenci P. |
| 臺大學術典藏 |
2021-09-04T06:11:17Z |
Hepatitis B surface antigen loss and hepatocellular carcinoma development in patients with dual hepatitis B and C infection
|
Yang W.-T.; Wu L.-W.; Tseng T.-C.; Chen C.-L.; Yang H.-C.; Su T.-H.; Wang C.-C.; Kuo S.F.-T.; Liu C.-H.; Chen P.-J.; Chen D.-S.; Liu C.-J.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:17Z |
Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection
|
Yang S.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:16Z |
How have the recent advances in antiviral therapy impacted the management of virus-related hepatocellular carcinoma?
|
Wang C.-C.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:16Z |
Perspectives on dual hepatitis B and C infection in Taiwan
|
Liu C.-J.; Chen P.-J.; Chen D.-S.; Tseng T.-C.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:15Z |
Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis
|
JIA-HORNG KAO; Jensen D.M.; Manns M.P.; Jacobson I.; Kumada H.; Toyota J.; Heo J.; Yoffe B.; Sievert W.; Bessone F.; Peng C.-Y.; Roberts S.K.; Lee Y.-J.; Bhore R.; Mendez P.; Hughes E.; Noviello S. |
| 臺大學術典藏 |
2021-09-04T06:11:15Z |
Management of hepatitis C patients with decompensated liver disease
|
Hsu C.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:15Z |
Efficacy of entecavir therapy for hepatitis B e-antigen positive chronic hepatitis B patients with prior exposure to interferon or nucleoside/nucleotide analogues
|
Tseng K.-C.; Tseng C.-W.; Hsieh T.-Y.; Peng C.-Y.; Lin C.-L.; Su T.-H.; Tseng T.-C.; Lin H.H.; Wang C.-C.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:14Z |
A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection
|
JIA-HORNG KAO; Chien R.-N.; Chang T.-T.; Peng C.-Y.; Hu T.-H.; Lo G.-H.; Wang H.-Y.; Chen J.-J.; Yang J.C.; Knox S.J.; Han L.; Mo H.; Mathias A.; Brainard D.M.; Sheen I.-S.; Hsu Y.-C.; Chu C.-J.; Chuang W.-L. |
| 臺大學術典藏 |
2021-09-04T06:11:14Z |
Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus
|
Chuang W.-L.; Chien R.-N.; Peng C.-Y.; Chang T.-T.; Lo G.-H.; Sheen I.-S.; Wang H.-Y.; Chen J.-J.; Yang J.C.; Knox S.J.; Gao B.; Garrison K.L.; Mo H.; Pang P.S.; Hsu Y.-C.; Hu T.-H.; Chu C.-J.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:14Z |
Review article: novel therapies for hepatitis B virus cure – advances and perspectives
|
Lin C.-L.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:13Z |
Assessing the Durability of Entecavir-Treated Hepatitis B Using Quantitative HBsAg
|
Wang C.-C.; Tseng K.-C.; Hsieh T.-Y.; Tseng T.-C.; Lin H.H.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:13Z |
Association of SCARB1 Gene Polymorphisms with Virological Response in Chronic Hepatitis C Patients Receiving Pegylated Interferon plus Ribavirin Therapy
|
Hsu C.-S.; Hsu S.-J.; Liu W.-L.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:13Z |
Liver gene expression profiles correlate with virus infection and response to interferon therapy in chronic hepatitis B patients
|
Wu H.-L.; Hsiao T.-H.; Chen P.-J.; Wong S.-H.; JIA-HORNG KAO; Chen D.-S.; Lu J.-Y.; Lu T.-P.; Chen Y.; Chuang E.Y.; Tu H.-C.; Liu C.-J. |
| 臺大學術典藏 |
2021-09-04T06:11:12Z |
APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing
|
Omata M.; Kanda T.; Wei L.; Yu M.-L.; Chuang W.-L.; Ibrahim A.; Lesmana C.R.A.; Sollano J.; Kumar M.; Jindal A.; Sharma B.C.; Hamid S.S.; Dokmeci A.K.; Al-Mahtab M.; McCaughan G.W.; Wasim J.; Crawford D.H.G.; JIA-HORNG KAO; Yokosuka O.; Lau G.K.K.; Sarin S.K. |
| 臺大學術典藏 |
2021-09-04T06:11:12Z |
APASL consensus statements and recommendation on treatment of hepatitis C
|
Omata M.; Kanda T.; Wei L.; Yu M.-L.; Chuang W.-L.; Ibrahim A.; Lesmana C.R.A.; Sollano J.; Kumar M.; Jindal A.; Sharma B.C.; Hamid S.S.; Dokmeci A.K.; Mamun-Al-Mahtab, McCaughan G.W.; Wasim J.; Crawford D.H.G.; JIA-HORNG KAO; Yokosuka O.; Lau G.K.K.; Sarin S.K. |
| 臺大學術典藏 |
2021-09-04T06:11:11Z |
All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study
|
JIA-HORNG KAO; Lee Y.-J.; Heo J.; Ahn S.-H.; Lim Y.-S.; Peng C.-Y.; Chang T.-T.; Torbeyns A.; Hughes E.; Bhore R.; Noviello S. |
| 臺大學術典藏 |
2021-09-04T06:11:10Z |
Association Between Serum Level of Hepatitis B Surface Antigen at End of Entecavir Therapy and Risk of Relapse in E Antigen–Negative Patients
|
Hsu Y.-C.; Mo L.-R.; Chang C.-Y.; Wu M.-S.; JIA-HORNG KAO; Wang W.-L.; Yang T.-H.; Wang C.-S.; Chiang M.-F.; Chen C.-C.; Fang Y.-J.; Hung H.-W.; Wu C.-Y.; Lin J.-T. |
| 臺大學術典藏 |
2021-09-04T06:11:10Z |
Reply
|
Su T.-H.; Chen C.-L.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:10Z |
Ritonavir-boosted danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis
|
JIA-HORNG KAO; Tung S.-Y.; Lee Y.; Thongsawat S.; Tanwandee T.; Sheen I.-S.; Wu J.J.; Li H.; Brennan B.J.; Zhou J.; Le Pogam S.; Najera I.; Thommes J.A.; Hill G. |
| 臺大學術典藏 |
2021-09-04T06:11:09Z |
Peginterferon Lambda-1a/ribavirin with daclatasvir or peginterferon alfa-2a/ribavirin with telaprevir for chronic hepatitis c genotype 1b
|
Flisiak R.; Kawazoe S.; Znoyko O.; Assy N.; Gadano A.; JIA-HORNG KAO; Lee K.-S.; Zwirtes R.; Portsmouth S.; Dong Y.; Xu D.; Kumada H.; Srinivasan S. |
| 臺大學術典藏 |
2021-09-04T06:11:09Z |
No Evidence of Reactivation of Hepatitis B Virus among Patients Treated with Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection
|
Sulkowski M.S.; Chuang W.-L.; JIA-HORNG KAO; Yang J.C.; Gao B.; Brainard D.M.; Han K.-H.; Gane E. |
| 臺大學術典藏 |
2021-09-04T06:11:09Z |
Prevalence and clinical implications of IL28B genotypes in Taiwanese patients with chronic hepatitis C
|
Mah Y.-H.; Liu C.-H.; Chen C.-L.; Tseng T.-C.; Liu C.-J.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:08Z |
Associated factors and clinical implications of serum aminotransferase elevation in scrub typhus
|
Su T.-H.; Liu C.-J.; Shu P.-Y.; Fu Y.-H.; Chang C.-H.; Jao P.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:08Z |
Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients
|
Su T.-H.; Hu T.-H.; Chen C.-Y.; Huang Y.-H.; Chuang W.-L.; Lin C.-C.; Wang C.-C.; Su W.-W.; Chen M.-Y.; Peng C.-Y.; Chien R.-N.; Huang Y.-W.; Wang H.-Y.; Lin C.-L.; Yang S.-S.; Chen T.-M.; Mo L.-R.; Hsu S.-J.; Tseng K.-C.; Hsieh T.-Y.; Suk F.-M.; Hu C.-T.; Bair M.-J.; Liang C.-C.; Lei Y.-C.; Tseng T.-C.; Chen C.-L.; JIA-HORNG KAO; the C-TEAM study group; the Taiwan Liver Diseases Consortium |
| 臺大學術典藏 |
2021-09-04T06:11:07Z |
Hepatitis B reactivation in patients receiving immunosuppressive therapy: a hidden menace
|
Lin C.-L.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:07Z |
Telbivudine therapy for chronic hepatitis B: A journey to identify super-responders and to optimize treatment using the roadmap model
|
JIA-HORNG KAO; Asselah T.; Dou X.-G.; Hamed K. |
| 臺大學術典藏 |
2021-09-04T06:11:07Z |
Pegylated IFN-α suppresses hepatitis C virus by promoting the DAPK-mTOR pathway
|
Liu W.-L.; Yang H.-C.; Hsu C.-S.; Wang C.-C.; Wang T.-S.; JIA-HORNG KAO; Chen D.-S. |
| 臺大學術典藏 |
2021-09-04T06:11:06Z |
NOhep: Toward Global Control of Hepatitis B Virus Infection - An Introduction
|
Liu C.-J.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:06Z |
High serum lipopolysaccharide-binding protein level in chronic hepatitis C viral infection is reduced by anti-viral treatments
|
Nien H.-C.; Hsu S.-J.; Su T.-H.; Yang P.-J.; Sheu J.-C.; Wang J.-T.; Chow L.-P.; Chen C.-L.; JIA-HORNG KAO; Yang W.-S. |
| 臺大學術典藏 |
2021-09-04T06:11:06Z |
Unmet Needs in Clinical and Basic Hepatitis B Virus Research
|
Su T.-H.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:06Z |
Targeting SHP-1-STAT3 signaling: A promising therapeutic approach for the treatment of cholangiocarcinoma
|
Hu M.-H.; Chen L.-J.; Chen Y.-L.; Tsai M.-S.; Shiau C.-W.; Chao T.-I.; Liu C.-Y.; JIA-HORNG KAO; Chen K.-F. |
| 臺大學術典藏 |
2021-09-04T06:11:05Z |
Response to Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in?chronic hepatitis B patients
|
Su T.-H.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:05Z |
Letter: HBsAg kinetics-guided interferon therapy for chronic hepatitis D
|
Kao C.-N.; Su T.-H.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:04Z |
Benefits of long-term therapy with nucleos(t)ide analogues in treatment-na?ve patients with chronic hepatitis B
|
Wei L.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:04Z |
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study
|
Blach S.; Zeuzem S.; Manns M.; Altraif I.; Duberg A.-S.; Muljono D.H.; Waked I.; Alavian S.M.; Lee M.-H.; Negro F.; Abaalkhail F.; Abdou A.; Abdulla M.; Abou Rached A.; Aho I.; Akarca U.; Al Ghazzawi I.; Al Kaabi S.; Al Lawati F.; Al Namaani K.; Al Serkal Y.; Al-Busafi S.A.; Al-Dabal L.; Aleman S.; Alghamdi A.S.; Aljumah A.A.; Al-Romaihi H.E.; Andersson M.I.; Arendt V.; Arkkila P.; Assiri A.M.; Baatarkhuu O.; Bane A.; Ben-Ari Z.; Bergin C.; Bessone F.; Bihl F.; Bizri A.R.; Blachier M.; Blasco A.J.; Brandao Mello C.E.; Bruggmann P.; Brunton C.R.; Calinas F.; Chan H.L.Y.; Chaudhry A.; Cheinquer H.; Chen C.-J.; Chien R.-N.; Choi M.S.; Christensen P.B.; Chuang W.-L.; Chulanov V.; Cisneros L.; Clausen M.R.; Cramp M.E.; Craxi A.; Croes E.A.; Dalgard O.; Daruich J.R.; De Ledinghen V.; Dore G.J.; El-Sayed M.H.; Ergor G.; Esmat G.; Estes C.; Falconer K.; Farag E.; Ferraz M.L.G.; Ferreira P.R.; Flisiak R.; Frankova S.; Gamkrelidze I.; Gane E.; Garcia-Samaniego J.; Khan A.G.; Gountas I.; Goldis A.; Gottfredsson M.; Grebely J.; Gschwantler M.; Guimaraes Pessoa M.; Gunter J.; Hajarizadeh B.; Hajelssedig O.; Hamid S.; Hamoudi W.; Hatzakis A.; Himatt S.M.; Hofer H.; Hrstic I.; Hui Y.-T.; Hunyady B.; Idilman R.; Jafri W.; Jahis R.; Janjua N.Z.; Jar?u?ka P.; Jeruma A.; Jonasson J.G.; Kamel Y.; JIA-HORNG KAO; Kaymakoglu S.; Kershenobich D.; Khamis J.; Kim Y.S.; Kondili L.; Koutoubi Z.; Krajden M.; Krarup H.; Lai M.-S.; Laleman W.; Lao W.-C.; Lavanchy D.; Lazaro P.; Leleu H.; Lesi O.; Lesmana L.A.; Li M.; Liakina V.; Lim Y.-S.; Luksic B.; Mahomed A.; Maimets M.; Makara M.; Malu A.O.; Marinho R.T.; Marotta P.; Mauss S.; Memon M.S.; Mendes Correa M.C.; Mendez-Sanchez N.; Merat S.; Metwally A.M.; Mohamed R.; Moreno C.; Mourad F.H.; Mullhaupt B.; Murphy K.; Nde H.; Njouom R.; Nonkovic D.; Norris S.; Obekpa S.; Oguche S.; Olafsson S.; Oltman M.; Omede O.; Omuemu C.; Opare-Sem O.; Ovrehus A.L.H.; Owusu-Ofori S.; Oyunsuren T.S.; Papatheodoridis G.; Pasini K.; Peltekian K.M.; Phillips R.O.; Pimenov N.; Poustchi H.; Prabdial-Sing N.; Qureshi H.; Ramji A.; Razavi-Shearer D.; Razavi-Shearer K.; Redae B.; Reesink H.W.; Ridruejo E.; Robbins S.; Roberts L.R.; Roberts S.K.; Rosenberg W.M.; Roudot-Thoraval F.; Ryder S.D.; Safadi R.; Sagalova O.; Salupere R.; Sanai F.M.; Sanchez Avila J.F.; Saraswat V.; Sarmento-Castro R.; Sarrazin C.; Schmelzer J.D.; Schreter I.; Seguin-Devaux C.; Shah S.R.; Sharara A.I.; Sharma M.; Shevaldin A.; Shiha G.E.; Sievert W.; Sonderup M.; Souliotis K.; Speiciene D.; Sperl J.; Starkel P.; Stauber R.E.; Stedman C.; Struck D.; Su T.-H.; Sypsa V.; Tan S.-S.; Tanaka J.; Thompson A.J.; Tolmane I.; Tomasiewicz K.; Valantinas J.; Van Damme P.; Van Der Meer A.J.; Van Thiel I.; Van Vlierberghe H.; Vince A.; Vogel W.; Wedemeyer H.; Weis N.; Wong V.W.S.; Yaghi C.; Yosry A.; Yuen M.-F.; Yunihastuti E.; Yusuf A.; Zuckerman E.; Razavi H.; The Polaris Observatory HCV Collaborators |
| 臺大學術典藏 |
2021-09-04T06:11:03Z |
Surveillance of hepatocellular carcinoma by magnetic resonance imaging with liver-specific contrast
|
Su T.-H.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:03Z |
Elimination of Hepatitis B: Is It a Mission Possible?
|
Tseng T.-C.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:03Z |
De novo assembly of highly polymorphic metagenomic data using in situ generated reference sequences and a novel BLAST-based assembly pipeline
|
Lin Y.-Y.; Hsieh C.-H.; Chen J.-H.; Lu X.; JIA-HORNG KAO; Chen P.-J.; Chen D.-S.; Wang H.-Y. |
| 臺大學術典藏 |
2021-09-04T06:11:02Z |
Natural history of acute and chronic hepatitis B: The role of HBV genotypes and mutants
|
Lin C.-L.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:02Z |
Urgency to treat patients with chronic hepatitis C in Asia
|
JIA-HORNG KAO; Ahn S.H.; Chien R.-N.; Cho M.; Chuang W.-L.; Jeong S.-H.; Liu C.-H.; Paik S.-W. |
| 臺大學術典藏 |
2021-09-04T06:11:02Z |
Treatment of de novo hepatitis C virus-related fibrosing cholestatic hepatitis after orthotopic heart transplantation by ledipasvir and sofosbuvir
|
Liu C.-H.; Chen Y.-S.; Wang S.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:01Z |
Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: A cohort study
|
Wang C.-C.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:01Z |
Letter: the influence of direct acting agents for hepatitis C, on hepatitis B reactivation
|
Wang C.-C.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:01Z |
HBV markers for HCC prediction: Three heads are better than two?
|
Tseng T.-C.; JIA-HORNG KAO |
